Together, these findings suggest that PAK2 could serve as a novel target to limit metastasis in breast cancer, and pharmacological PAK2 inhibitors such as FRAX597 could provide multiple therapeutic benefits, including limiting tumor progression, reducing metastasis and improving patient outcomes. Here, PAK2 is linked to breast carcinoma.